SEC Form 4 · accession 0001209191-16-139032
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lewis T Williams
Officer — President, CEO and Chairman · Director
Period of report
Aug 25, 2016
Accepted (ET)
Aug 29, 2016 · 6:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 25, 2016 | A | 42,500 | $0.00 | A | 464,328 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $43.71 | Aug 25, 2016 | A | 180,000 | A | — | Aug 25, 2026 | Common Stock | 180,000 | 180,000 | D |
Explanation of responses
- F1Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of September 1, 2017, 2018 and 2019.
- F2The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month starting September 25, 2016, provided the reporting person remains employed by Five Prime Therapeutics, Inc., through each such date.